Original news and analysis on international IP policy
The Medicines Patent Pool announced today that it has signed a license agreement with Johns Hopkins University for a candidate tuberculosis treatment. Although seen as a major step forward by public health groups, they said the agreement does not include guarantees that the treatment that could be brought to the market would be affordable for all.
Just a day after US President Donald Trump withdrew the United States from the Trans-Pacific Partnership, the International Trade Committee of the European Parliament passed a recommendation in favour of adopting the Comprehensive Economic and Trade Agreement (CETA) between Canada and the EU. Meanwhile, the EU Trade Commissioner said trade is not to blame and the EU will negotiate many trade deals this year.
World Health Organization members took the first step toward choosing the next director general of the UN health agency today as they narrowed the candidates to five. There will be interviews held with the remaining candidates tomorrow, after which the list will be reduced to three until the May World Health Assembly.
More than a decade after World Trade Organization member states approved the first-ever legal amendment to a WTO agreement, the change to the international intellectual property agreement has entered into effect. Five more members ratified the amendment in recent days, bringing supporters over the minimum needed to put into effect the amendment aimed at boosting exports of medical products made under compulsory licence.
At the opening of the World Health Organization Executive Board meeting today, a call by India for an agenda item on the report of the United Nations Secretary-General’s High-Level Panel on Access to Medicines was denied. Meanwhile, WHO’s director general underlined the success of the organisation over the last year, including new financing arrangements with industry groups to finance the WHO Prequalification Programme. But all eyes are riveted to the election process for the new WHO director general, as three out of the six candidates are expected to be short-listed this week.
BANGKOK – So-called disruptive innovation - currently referring to the technologies of Internet of Things, virtual reality, artificial intelligence and big data – are changing the way people live their life and affecting existing traditional industries, but current legal regimes are unequipped to deal with these changes yet, government and private experts said at a recent forum here.
George Willingmyre writes: The process a Standards Developing Organization (SDO) employs to revise its patent policy is an aspect of the SDO’s competitive posture in the global marketplace. A dearth of research exists on the processes SDOs employ to revise their patent policies. Generally, the processes an SDO uses to revise its patent policy are part of the governance processes of the SDO. As a baseline, the governance processes of an SDO must be consistent with the applicable legal system defining what is acceptable and unacceptable behavior. What an SDO says about its governance processes is a further consideration. Thus the procedures themselves, the procedures’ relationship to the applicable legal system and what the SDO says about the procedures all play a role in understanding how an SDO revises its patent policy.
Whatever else could be said of 2016, it was undeniably interesting. That’s likely to be true, too, for 2017. Even the staid area of US Intellectual Property Law may face dramatic changes. Here's the likely most important of those changes.
It is too early to push the panic button with regard to the rise of protectionism under new US President Donald Trump, David Cote, CEO of US multinational Honeywell, said on a panel discussion at the World Economic Forum today in Davos.
A range of civil society organisations have issued a public statement opposing the United States Army’s proposed grant of an exclusive licence on technology necessary to produce a Zika vaccine to French pharmaceutical company Sanofi. The letter cites concerns that the exclusive licence might violate US law and could lead to high priced medicines as consumers buy back taxpayer-funded research.
The lack of an intellectual property regime for animal breeding in Kenya is undermining efforts to curb illegal exploitation of Kenyan animal genetic resources, according to industry representatives.
Nearly two dozen top biopharmaceutical companies have launched a global initiative intended to increase access to prevention and care of non-transmitted diseases in low and lower-middle income countries.